newsfilter
← Latest News
Business Wire·

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Patent-protected aminated tryptamine derivatives strengthen Enveric's leadership in next-generation mental health treatments Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company